Posted by Michael Wonder on 09 May 2023
Eyenovia announces FDA approval of Mydcombi, the first ophthalmic spray for mydriasis, which also leverages the company’s proprietary Optejet device platform
8 May 2023 - Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis.
Eyenovia today announced that the US FDA has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired.
